ClinConnect ClinConnect Logo
Search / Trial NCT00671346

NORVIT and WENBIT - Long-term Follow-up

Launched by HAUKELAND UNIVERSITY HOSPITAL · Apr 29, 2008

Trial Information

Current as of June 10, 2025

Unknown status

Keywords

Cancer Coronary Artery Disease Myocardial Infarction Cerebrovascular Stroke Homocysteine Vitamin B Complex Folic Acid Vitamin B12 Vitamin B6 Pyridoxal Phosphate Osteoporotic Fractures Diabetes

ClinConnect Summary

The "homocysteine-hypothesis" of vascular disease has attracted considerable interest, as total plasma homocysteine levels can be easily lowered by folic acid and vitamin B12, raising the prospect that cardiovascular disease could be lowered by such B-vitamin supplementation.

Two large B-vitamin intervention trials have been performed in Norway during the period 1998 to 2005, NORVIT and WENBIT, both registered at ClinicalTrials.gov, identifiers NCT00266487 and NCT00354081, respectively. The main objective in these trials was to study the effects of homocysteine-lowering therapy with folic ...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Randomised in the Norwegian Vitamin Trial (NORVIT) or in the Western Norway B-Vitamin Intervention Trial (WENBIT)
  • Exclusion Criteria:
  • Withdrawn consent to participate in study cohort for post-trial observational follow-up

About Haukeland University Hospital

Haukeland University Hospital, located in Bergen, Norway, is a leading academic medical center renowned for its commitment to innovative research and high-quality patient care. As a prominent clinical trial sponsor, the hospital leverages its extensive expertise in various medical fields to facilitate cutting-edge clinical studies that aim to advance healthcare outcomes. With a multidisciplinary team of healthcare professionals and researchers, Haukeland University Hospital fosters collaboration and knowledge exchange, ensuring that trials are conducted with the highest standards of ethics, safety, and scientific rigor. Its strategic focus on translational research enhances the bridge between laboratory discoveries and real-world applications, contributing to the global body of medical knowledge.

Locations

Bergen, , Norway

Tromsø, , Norway

Patients applied

0 patients applied

Trial Officials

Ottar Nygård, MD, PhD

Study Chair

Department of Heart Disease, Haukeland University Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials